About Oncolytics Biotech Inc. - Common Shares (ONCY)
Oncolytics Biotech Inc is a biotechnology company focused on developing innovative cancer therapies using a proprietary virus-based approach. The company’s leading product candidate is a proprietary oncolytic virus designed to selectively target and destroy cancer cells while sparing normal healthy tissue. By harnessing the power of the immune system in combination with the virus, Oncolytics aims to create more effective treatment options for various types of cancer, ultimately enhancing patient outcomes. The company is actively involved in clinical trials to evaluate the safety and efficacy of its treatments, contributing to the advancement of cancer care. Read More
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual property (“IP”) portfolio and ongoing efforts to extend patent protection for pelareorep as part of the company’s long-term value creation and development strategy.
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal (“GI”) Tumor Scientific Advisory Board (“SAB”) with the appointment of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris, three globally recognized experts in gastrointestinal oncology. The GI SAB was recently established to support Oncolytics’ growing portfolio of clinical programs in pancreatic, colorectal, and anal cancers and to guide the Company’s strategy as it advances pelareorep as a platform immunotherapy across GI tumors.
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced clinical and translational findings supporting the development of pelareorep in second-line metastatic colorectal cancer (“mCRC”), specifically in patients with KRAS-mutant, microsatellite-stable (“MSS”) disease. This represents one of the most difficult-to-treat and least responsive subgroups within colorectal cancer.
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amended registration statement on Form F-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) that includes a management circular/prospectus and other relevant documents related to various proposals contained therein, and that the Registration Statement has been declared effective by the SEC. The Company has rescheduled its special meeting of shareholders (the “Special Meeting”), as described in previous news releases, to January 15, 2026 at 10:00 a.m. (Eastern Time). The record date for shareholders entitled to attend and vote at the Special Meeting is December 9, 2025.
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has cancelled and will reschedule its special meeting of shareholders (the “Special Meeting”), as described in its news release dated October 20, 2025, which was to be held on December 15, 2025. The Special Meeting is being rescheduled due to delays at the Securities and Exchange Commission caused by the recent shutdown of the federal government in the United States. Once rescheduled, the Special Meeting will be held in order to vote on, among other things, a series of transactions that would change the jurisdiction of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States (the “Domestication”).
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment paradigms for historically difficult cancers. Leading researchers showcased breakthrough advances in immunotherapy at recent oncology conferences, highlighting next-generation approaches that selectively target tumor-specific vulnerabilities. This wave of innovation is propelling companies developing targeted therapies across gastrointestinal, blood, and solid tumor cancers, including Oncolytics Biotech Inc. (NASDAQ: ONCY), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Erasca, Inc. (NASDAQ: ERAS), Immuneering Corporation (NASDAQ: IMRX), and Prelude Therapeutics Incorporated (NASDAQ: PRLD).
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug Administration (“FDA”) regarding the design of its pivotal study of pelareorep in combination with standard-of-care therapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the formation of its Gastrointestinal (GI) Tumor Scientific Advisory Board (SAB), a group of leading oncology experts assembled to guide the Company’s clinical and regulatory strategy for developing pelareorep as a treatment for GI cancers.
Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile […]
PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors are driving this expansion, including rising cancer incidence, advancements in therapies like precision medicine and immunotherapy, and increased investment in research and development. A report from Grand View Research said that the global breakthrough therapy designation market size is projected to grow at a CAGR of 14.2% through 2030. It is a process designed to escalate the development and assessment of sanctioning of drugs & biologics that are proposed for treating severe diseases, whereas primary clinical evidence notifies that the drug determines considerable enhancement over existing therapy on a clinically significant endpoint. Furthermore, the BT (Breakthrough) designation lets pharma companies hasten the developmental process by offering additional support and assistance from the FDA and making medications available to the public faster. The report continued: “Apart from breakthrough designation therapy, there are some important tools, all of which have been in place for many years, such as fast-track designation, accelerated approval, and priority review. All of these are inclined toward approving drugs used to treat serious disorders. Although these processes can reduce a drug's time to market, standard clinical testing is required for the development process, which usually involves three phases of large-scale and controlled trials.” Active oncology biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Mustang Bio, Inc. (NASDAQ: MBIO), Verastem Oncology (NASDAQ: VSTM), Cardiff Oncology, Inc. (NASDAQ: CRDF), AstraZeneca PLC (NASDAQ: AZN).
